Cargando…

Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China

In 2002, China integrated hepatitis B vaccine (HepB) into its Expanded Program on Immunization (EPI) using HepB vaccine containing 5 µg of antigen. Although not recommended nationally, there was a common clinical practice in China of screening children for anti-HBs antibody level and giving a booste...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Ning, Zheng, Hui, Sun, Xiaojin, Zhang, Guomin, Wang, Fuzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584599/
https://www.ncbi.nlm.nih.gov/pubmed/33097788
http://dx.doi.org/10.1038/s41598-020-75338-5
_version_ 1783599628033196032
author Miao, Ning
Zheng, Hui
Sun, Xiaojin
Zhang, Guomin
Wang, Fuzhen
author_facet Miao, Ning
Zheng, Hui
Sun, Xiaojin
Zhang, Guomin
Wang, Fuzhen
author_sort Miao, Ning
collection PubMed
description In 2002, China integrated hepatitis B vaccine (HepB) into its Expanded Program on Immunization (EPI) using HepB vaccine containing 5 µg of antigen. Although not recommended nationally, there was a common clinical practice in China of screening children for anti-HBs antibody level and giving a booster dose to HBV surface antigen (HBsAg)-negative children with non-protective anti-HBs antibody levels. We report an evaluation of the protective effectiveness of the 5 µg HepB vaccine and the serological response to the booster dose. We used data from a 2014 hepatitis B serological survey to determine HBsAg positivity and anti-HBs antibody levels among children who received and did not receive a booster dose. We determined HepB coverage from the Children Immunization Information Management System (CIIMS). We obtained and analyzed reports of acute Hepatitis B (AHB) during 2008–2014 obtained from the National Notifiable Disease Reporting System (NNDRS). The HBsAg-positive rate among children who had not received a booster dose was 0.41%, and did not increase with age (i.e., time since infant immunization). The anti-HBs positivity rate among the 6% of children who received a booster dose (88.41%) was higher than among those who had not received a booster (60.85%); anti-HBs antibody levels declined with age regardless of booster dose status. There was no statistically significant difference in HBsAg positivity between children who received a booster dose and those who did not. The AHB incidence among children born between 2002 and 2007 did not increase with age. Use of routine 5 µg HepB vaccine was not associated with an increase in AHB or of HBsAg positivity by time since vaccination, providing supportive evidence that individuals vaccinated with the 5 µg HepB vaccine do not need a booster dose. Although a booster dose was associated with increases in anti-HBs antibody levels, our study provided no evidence to support the need for this clinical practice. We should continue to strengthen serological monitoring of children, especially for those born to HBsAg positive mothers.
format Online
Article
Text
id pubmed-7584599
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75845992020-10-27 Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China Miao, Ning Zheng, Hui Sun, Xiaojin Zhang, Guomin Wang, Fuzhen Sci Rep Article In 2002, China integrated hepatitis B vaccine (HepB) into its Expanded Program on Immunization (EPI) using HepB vaccine containing 5 µg of antigen. Although not recommended nationally, there was a common clinical practice in China of screening children for anti-HBs antibody level and giving a booster dose to HBV surface antigen (HBsAg)-negative children with non-protective anti-HBs antibody levels. We report an evaluation of the protective effectiveness of the 5 µg HepB vaccine and the serological response to the booster dose. We used data from a 2014 hepatitis B serological survey to determine HBsAg positivity and anti-HBs antibody levels among children who received and did not receive a booster dose. We determined HepB coverage from the Children Immunization Information Management System (CIIMS). We obtained and analyzed reports of acute Hepatitis B (AHB) during 2008–2014 obtained from the National Notifiable Disease Reporting System (NNDRS). The HBsAg-positive rate among children who had not received a booster dose was 0.41%, and did not increase with age (i.e., time since infant immunization). The anti-HBs positivity rate among the 6% of children who received a booster dose (88.41%) was higher than among those who had not received a booster (60.85%); anti-HBs antibody levels declined with age regardless of booster dose status. There was no statistically significant difference in HBsAg positivity between children who received a booster dose and those who did not. The AHB incidence among children born between 2002 and 2007 did not increase with age. Use of routine 5 µg HepB vaccine was not associated with an increase in AHB or of HBsAg positivity by time since vaccination, providing supportive evidence that individuals vaccinated with the 5 µg HepB vaccine do not need a booster dose. Although a booster dose was associated with increases in anti-HBs antibody levels, our study provided no evidence to support the need for this clinical practice. We should continue to strengthen serological monitoring of children, especially for those born to HBsAg positive mothers. Nature Publishing Group UK 2020-10-23 /pmc/articles/PMC7584599/ /pubmed/33097788 http://dx.doi.org/10.1038/s41598-020-75338-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Miao, Ning
Zheng, Hui
Sun, Xiaojin
Zhang, Guomin
Wang, Fuzhen
Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title_full Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title_fullStr Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title_full_unstemmed Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title_short Protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China
title_sort protective effect of vaccinating infants with a 5 µg recombinant yeast-derived hepatitis b vaccine and the need for a booster dose in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584599/
https://www.ncbi.nlm.nih.gov/pubmed/33097788
http://dx.doi.org/10.1038/s41598-020-75338-5
work_keys_str_mv AT miaoning protectiveeffectofvaccinatinginfantswitha5μgrecombinantyeastderivedhepatitisbvaccineandtheneedforaboosterdoseinchina
AT zhenghui protectiveeffectofvaccinatinginfantswitha5μgrecombinantyeastderivedhepatitisbvaccineandtheneedforaboosterdoseinchina
AT sunxiaojin protectiveeffectofvaccinatinginfantswitha5μgrecombinantyeastderivedhepatitisbvaccineandtheneedforaboosterdoseinchina
AT zhangguomin protectiveeffectofvaccinatinginfantswitha5μgrecombinantyeastderivedhepatitisbvaccineandtheneedforaboosterdoseinchina
AT wangfuzhen protectiveeffectofvaccinatinginfantswitha5μgrecombinantyeastderivedhepatitisbvaccineandtheneedforaboosterdoseinchina